Expertise in
10
conditions

Dr. Laith I. Abushahin

Oncology
3410 Worth Street, Suite 400, 
Dallas, TX 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
10
conditions
3410 Worth Street, Suite 400, 
Dallas, TX 

Overview

Laith Abushahin is an Oncologist practicing medicine in Dallas, Texas.

Dr. Abushahin is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Pancreatic Cancer, Familial Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Familial Colorectal Cancer, and Pancreatectomy.

Dr. Abushahin is board certified in Medical Oncology- American Board Of Internal Medicine, Medical Oncology- American Board Of Internal Med/Medical Oncology, Internal Medicine- American Board Of Internal Med, and Internal Medicine- American Board Of Internal Medicine. He is actively involved in clinical research, co-authoring 19 peer reviewed articles and participating in 8 clinical trials. Dr. Abushahin is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in IA

Board Certifications

Medical Oncology- American Board Of Internal Medicine
Medical Oncology- American Board Of Internal Med/Medical Oncology
Internal Medicine- American Board Of Internal Med
Internal Medicine- American Board Of Internal Medicine

Fellowships

Medical Oncology, Baylor University Medical Center - 2013

Hospital Affiliations

Baylor Scott & White Institute For Rehabilitation - Dallas
Baylor Scott & White The Heart Hospital - Dallas
Baylor University Medical Center, Part Of Baylor Scott & White Health
Baylor Scott & White The Heart Hospital - Plano
Baylor Scott & White The Heart Hospital - Denton
Baylor University Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
FirstCare
  • HMO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Texas Oncology, P.A.
3410 Worth Street, Suite 400, Dallas, TX 75246

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Suspended
Publish Date: September 01, 2026
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
Study Phase: Phase 2/Phase 3
A Pilot Study of Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma
A Pilot Study of Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: August 12, 2026
Intervention Type: Drug
Study Drugs: Gemcitabine, Nab-paclitaxel
Study Phase: Phase 2
A Phase I Study of Anetumab Ravtansine in Combination With Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
A Phase I Study of Anetumab Ravtansine in Combination With Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD-1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: July 21, 2026
Intervention Type: Biological, Procedure, Drug
Study Drugs: Anetumab ravtansine, Gemcitabine hydrochloride, Ipilimumab, Nivolumab
Study Phase: Phase 1
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Completed
Publish Date: December 31, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
Randomized Study of Early Palliative Care Integrated With Standard Oncology Care Versus Standard Oncology Care Alone in Patients With Incurable Lung or Non-Colorectal Gastrointestinal Malignancies
Randomized Study of Early Palliative Care Integrated With Standard Oncology Care Versus Standard Oncology Care Alone in Patients With Incurable Lung or Non-Colorectal Gastrointestinal Malignancies
Enrollment Status: Completed
Publish Date: February 07, 2025
Intervention Type: Other
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in Combination With Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX as Neoadjuvant Treatment in Patients With Locally Advanced, Unresectable Pancreatic Cancer
Enrollment Status: Completed
Publish Date: November 05, 2024
Intervention Type: Drug
Study Drugs: Pamrevlumab, Gemcitabine, Nab-paclitaxel, FOLFIRINOX
Study Phase: Phase 3
A Phase II Study Evaluating Safety and Efficacy of Durvalumab (MEDI4736) Following Multi-modality Therapy in Esophageal Cancer: Big Ten Cancer Research Consortium BTCRC-ESO14-012
A Phase II Study Evaluating Safety and Efficacy of Durvalumab (MEDI4736) Following Multi-modality Therapy in Esophageal Cancer: Big Ten Cancer Research Consortium BTCRC-ESO14-012
Enrollment Status: Completed
Publish Date: September 25, 2023
Intervention Type: Drug
Study Drug: Durvalumab
Study Phase: Phase 2
A Phase 1b Study: Treatment of Refractory Pancreatic Adenocarcinoma and Advanced Soft Tissue or Bone Sarcomas Using Decitabine Combined With Gemcitabine
A Phase 1b Study: Treatment of Refractory Pancreatic Adenocarcinoma and Advanced Soft Tissue or Bone Sarcomas Using Decitabine Combined With Gemcitabine
Enrollment Status: Completed
Publish Date: July 28, 2023
Intervention Type: Drug
Study Drugs: Decitabine, Gemcitabine
Study Phase: Phase 1
View 7 Less Clinical Trials

19 Total Publications

Simultaneous resection of pancreatic cancer and liver metastases following total neoadjuvant therapy: A case series and analysis of the National Cancer Database.
Simultaneous resection of pancreatic cancer and liver metastases following total neoadjuvant therapy: A case series and analysis of the National Cancer Database.
Journal: Annals of hepato-biliary-pancreatic surgery
Published: October 23, 2025
Similar Doctors
Expertise in
38
conditions
Dr. Farrukh T. Awan
Hematology | Oncology
Expertise in
38
conditions
Dr. Farrukh T. Awan
Hematology | Oncology
Referral may be required

UT Southwestern-Bill And Rita Clements Advanced Medical Imaging Center

2201 Inwood Rd, 
Dallas, TX 
 (4.3 miles away)
214-645-4673
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Farrukh Awan is a Hematologist and an Oncologist practicing medicine in Dallas, Texas. Dr. Awan is highly rated in 38 conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
14
conditions
Expertise in
14
conditions
Referral required
Before you request

Texas Oncology, P.A.

3410 Worth Street, Suite 400, 
Dallas, TX 
 (0.1 miles away)
214-370-1000
Experience:
44+ years
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. O'Shaughnessy is a Medical Oncologist that focuses on breast cancer prevention and treatment. She founded The School of Breast Oncology, a program providing a curriculum-based program focused exclusively on breast cancer clinical management. Dr. O'Shaughnessy attended medical school at Yale University School of Medicine in New Haven, CT. She then completed her Internal Medicine residency at Massachusetts General Hospital in Boston, MA and a Medical Oncology fellowship at National Cancer Institute in Bethesda, MD. She is co-chair of Breast Cancer Research, chair of Breast Cancer Prevention Research at Baylor Charles A. Sammons Cancer Center and a member of the Scientific Advisory Board for US Oncology Research Network. Dr. O'shaughnessy is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, PIK3CA-Related Overgrowth Spectrum, Inflammatory Breast Cancer, and Tissue Biopsy. Dr. O'shaughnessy is board certified in Medical Oncology- American Board Of Internal Medicine, Medical Oncology- American Board Of Internal Med/Medical Oncology, Internal Medicine- American Board Of Internal Med, and Internal Medicine- American Board Of Internal Medicine. Dr. O'shaughnessy is currently accepting new patients.

Expertise in
10
conditions
Expertise in
10
conditions
Referral may be required

Office

2201 Inwood Rd, 
Dallas, TX 
 (4.3 miles away)
214-645-4673
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Hans Hammers is an Oncologist practicing medicine in Dallas, Texas. Dr. Hammers is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Wilms Tumor, Nephrectomy, and Thrombectomy.

Frequently Asked Questions about Dr. Laith I. Abushahin

How do I make an appointment with Dr. Laith I. Abushahin?

You can book an appointment with Dr. Laith I. Abushahin by calling their office at 214-370-1300. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Laith I. Abushahin a top-rated expert for Pancreatic Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Laith I. Abushahin is classified as an Distinguished expert for Pancreatic Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Laith I. Abushahin specialize in?

While Dr. Laith I. Abushahin is a Oncology, they have specific expertise in Pancreatic Cancer, Familial Pancreatic Cancer, and Cholangiocarcinoma (Bile Duct Cancer). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Laith I. Abushahin participate in research or clinical trials?

Yes. Dr. Laith I. Abushahin has published 19 articles and abstracts on conditions like Pancreatic Cancer. You can view a list of Dr. Laith I. Abushahin's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Laith I. Abushahin accept my insurance?

Dr. Laith I. Abushahin accepts most major insurance plans, including Aetna and Baylor Scott & White Health. We recommend calling the office directly at 214-370-1300 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Abushahin's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 30 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile